clinical trial · NCT06258668
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Bristol-Myers Squibb·—·recruiting·n = 505
Moderate-to-severe Plaque PsoriasisDeucravacitinib
brief summary
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
started
Aug 21, 2024
primary completion
Sep 30, 2028
completion
Sep 30, 2028
last updated
Nov 6, 2024
official title
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol